Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06413498 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
A Phase 3 study of Multiple Myeloma, sponsored by Kite, A Gilead Company.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 20
- Study locations
NCT06413498: Recruiting Phase 3 study of Multiple Myeloma, sponsored by Kite, A Gilead Company.
NCT06413498 is a Phase 3 study of Multiple Myeloma that is actively recruiting participants, run by Kite, A Gilead Company. The registered enrollment target is 450 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (18% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06413498, a Phase 3 study of Multiple Myeloma, is actively recruiting participants, sponsored by Kite, A Gilead Company.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Pomalidomide
- DRUG Bortezomib
- DRUG Anitocabtagene Autoleucel
Study Locations (20)
California
- City of Hope (City of Hope National Medical Center, City of Hope Medical Center) - Duarte
- USC/Norris Comprehensive Cancer Center - Los Angeles
- University of California Davis Comprehensive Cancer Center - Sacramento
- UC San Diego Moores Cancer Center - San Diego
- University of California San Francisco Medical Center - San Francisco
- UCLA Hematology/Oncology (Bowyer Infusion Clinic) - Santa Monica
- Stanford Cancer Institute - Stanford
Florida
- Sylvester Comprehensive Cancer Center - Coral Gables
- Mayo Clinic - Jacksonville
- Moffitt Cancer Center - Tampa
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- Mayo Clinic Hospital - Gilbert
Georgia
- Winship Cancer Institute, Emory University - Atlanta
- Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta - Newnan
Colorado
- Colorado Blood Cancer Institute - Denver
Idaho
- St. Luke's Cancer Institute - Boise
Illinois
- University of Illinois Hospital and Health Sciences System - Chicago
Indiana
- IU Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2024-08-23 |
| Est. Completion | 2031-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06413498
The ClinicalTrials.gov registry entry for NCT06413498 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 450 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (18% lower). The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06413498 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT06413498 about?
NCT06413498 is a clinical study titled "A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma". The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory...
What is the current status of trial NCT06413498?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2024-08-23. Estimated completion is 2031-07.
What conditions does trial NCT06413498 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT06413498?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Pomalidomide (DRUG), Bortezomib (DRUG), Anitocabtagene Autoleucel (DRUG).
Who is sponsoring clinical trial NCT06413498?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06413498 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.